Raptor Pharmaceutical Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Raptor Pharmaceutical Corp.
Royal Philips would not routinely invest 10% of its sales in R&D without working with providers to discover their precise needs, says CEO Frans van Houten.
Philips reported $4.97bn in sales for the second quarter of 2020, a 6% decline compared to the second quarter of last year. While the pandemic slowed down demand across the business, Philips connected care business increased by 14% due to demand for respiratory devices.
How quickly health care delivery returns to pre-COVID-19 routines is the million-dollar question. With coronavirus volatility still a worrying reality and the burden of chronic care ever present, medtech companies that partner with provider systems must ensure they are covering all the bases. For Royal Philips’ Roy Jakobs, this means delivering on the promises of connected care.
The biopharmaceutical industry is expanding its presence on college campuses to address a shortage of workers proficient in advanced manufacturing, cell and gene therapies and combination products. Executives say that not having enough of these skilled workers keeps them up at night.
- Other Names / Subsidiaries
- Encode Pharmaceuticals, Inc.
- TorreyPines Therapeutics, Inc. (Neurogenetics Inc.)